Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Iressa Activity Not Likely Predicted By EGFR Expression Level – AstraZeneca

Executive Summary

The level of EGFR expression seen in solid tumors is not a likely predictor of clinical activity observed with Iressa, AstraZeneca Iressa Global Product Director Linda Summerton said Nov. 7

You may also be interested in...



OSI Developing Tarceva I.V. Formulation, Expected To Aid In Reimbursement

OSI Pharmaceuticals is developing an intravenous formulation of its investigational anticancer agent Tarceva, which should facilitate reimbursement for the investigational anticancer agent

OSI Developing Tarceva I.V. Formulation, Expected To Aid In Reimbursement

OSI Pharmaceuticals is developing an intravenous formulation of its investigational anticancer agent Tarceva, which should facilitate reimbursement for the investigational anticancer agent

AstraZeneca Prices Iressa At 25% Discount To Gleevec; Launch In May

AstraZeneca is launching the lung cancer agent Iressa at a 25% discount to Novartis' chronic myelogenous leukemia therapy Gleevec

Related Content

UsernamePublicRestriction

Register

PS040766

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel